Last reviewed · How we verify
HL036 Ophthalmic Solution — Competitive Intelligence Brief
phase 3
Ophthalmology
Biologic
Live · refreshed every 30 min
Target snapshot
HL036 Ophthalmic Solution (HL036 Ophthalmic Solution) — HanAll BioPharma Co., Ltd.. HL036 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HL036 Ophthalmic Solution TARGET | HL036 Ophthalmic Solution | HanAll BioPharma Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HL036 Ophthalmic Solution CI watch — RSS
- HL036 Ophthalmic Solution CI watch — Atom
- HL036 Ophthalmic Solution CI watch — JSON
- HL036 Ophthalmic Solution alone — RSS
Cite this brief
Drug Landscape (2026). HL036 Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/hl036-ophthalmic-solution. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing